Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, First-in-Human, Dose Escalation Trial of MSC2363318A, a Dual p70S6K/Akt Inhibitor, in Subjects With Advanced Malignancies

Trial Profile

A Phase I, First-in-Human, Dose Escalation Trial of MSC2363318A, a Dual p70S6K/Akt Inhibitor, in Subjects With Advanced Malignancies

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 12 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rupitasertib (Primary) ; Elacestrant; Tamoxifen; Trastuzumab
  • Indications HER2 negative breast cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors EMD Serono
  • Most Recent Events

    • 19 Apr 2023 Results (n=20) assessing the exploratory correlative analyses in ER+ HER2-negative metastatic breast cancer patients in addition to nonclinical experiments to evaluate its role in the CDK4/6 and endocrine therapy (ET) resistant setting, presented at the 114th Annual Meeting of the American Association for Cancer Research.
    • 06 Apr 2023 According to Diaccurate Media Release, DIACC3010, expectedto enter phase 2/3 clinical trial in refractory ER positive and HER negative Metastatic breast cancer and phase 1 trial in glioblastoma multiforme.
    • 06 Apr 2023 According to Diaccurate Media Release, the company has been selected to present new nonclinical efficacy and clinical exploratory correlative analysis of DIACC3010 in metastatic ER positive and HER Negative breast cancer at American Association of Cancer Research (AACR) Annual meeting 2023 in Prlando FL.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top